AHPA saw palmetto claim
This article was originally published in The Tan Sheet
Executive Summary
"There is no basis to conclude that consumers will improperly use" supplements containing saw palmetto if they feature a health claim, AHPA maintains in amicus brief filed May 28. FDA concern that men may self-medicate with saw palmetto and delay diagnosis of other conditions such as cancer "could be fully addressed through a requirement that the saw palmetto health claim be accompanied by information about the need for regular prostate exams," group states. Adding such language "would benefit, not harm, the public health," AHPA adds. Emord & Associates appealed lower court ruling upholding FDA's decision to deny claim in May (1"The Tan Sheet" May 26, 2003, p. 13)...
You may also be interested in...
Health Claims Law Includes Effect On Existing Disease – Saw Palmetto Appeal
A Washington, D.C. federal court committed a "plain and reversible error" when it upheld FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hyperplasia symptoms, according to an appellate brief filed May 16
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.